Synopsis
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Histidine, L Isomer
2. Histidine, L-isomer
3. L-histidine
4. L-isomer Histidine
1. L-histidine
2. 71-00-1
3. H-his-oh
4. Glyoxaline-5-alanine
5. L-(-)-histidine
6. Anti-rheuma
7. Istidina
8. S-histidine
9. (l)-histidine
10. Histidine (van)
11. Histidine, L-
12. Histidina
13. (s)-4-(2-amino-2-carboxyethyl)imidazole
14. (2s)-2-amino-3-(1h-imidazol-4-yl)propanoic Acid
15. L-histidin
16. (s)-alpha-amino-1h-imidazole-4-propanoic Acid
17. Fema No. 3694
18. Histidine [usan:inn]
19. Histidinum [inn-latin]
20. (s)-histidine
21. Histidina [inn-spanish]
22. L-beta-(4-imidazolyl)alanin
23. 4-(2-amino-2-carboxyethyl)imidazole
24. His
25. L-hystidine
26. 1h-imidazole-4-alanine, (s)-
27. L-hisidine
28. (s)-2-amino-3-(4-imidazolyl)propionsaeure
29. L-beta-(4-imidazolyl)-alpha-alanin
30. (s)-alpha-amino-1h-imidazole-4-propionic Acid
31. L-his
32. L-alanine, 3-(1h-imidazol-4-yl)-
33. Ai3-26558
34. Alpha-amino-4(or 5)-imidazolepropionic Acid
35. Histidine (l-histidine)
36. Alpha-amino-1h-imidazole-4-propionic Acid, (s)-
37. 1h-imidazole-4-propanoic Acid, Alpha-amino-, (s)-
38. (s)-a-amino-1h-imidazole-4-propanoic Acid
39. (s)-2-amino-3-(4-imidazolyl)propionic Acid
40. Chebi:15971
41. 4qd397987e
42. Nsc-137773
43. 7006-35-1
44. Histidinum
45. Mfcd00064315
46. (2s)-2-amino-3-(imidazol-4-yl)propanoic Acid
47. Histidine, Monohydrochloride
48. Hsdb 1810
49. Einecs 200-745-3
50. Nsc 137773
51. Unii-4qd397987e
52. 1hsl
53. 1lag
54. [3h]histidine
55. Histidine,(s)
56. [3h]-histidine
57. (2s)-2-amino-3-(1h-imidazol-4-yl)propanoic Acid Hydrochloride
58. Histidine (usp/inn)
59. Histidine [inn]
60. Histidine [ii]
61. Histidine [mi]
62. L-histidine (jp17)
63. L-2-amino-3-(4-imidazolyl)propionic Acid
64. Histidine [hsdb]
65. Histidine [inci]
66. Histidine [usan]
67. Histidine [vandf]
68. Lopac-h-8125
69. Bmse000039
70. Bmse000976
71. Bmse001015
72. Histidine [mart.]
73. L-histidine [fcc]
74. L-histidine [jan]
75. L-histidine (h-his-oh)
76. Amino-4-imidazoleproprionate
77. Histidine [who-dd]
78. L-histidine [fhfi]
79. Schembl3259
80. Lopac0_000566
81. Us9138393, Histidine
82. Us9144538, Histidine
83. (s)1h-imidazole-4-alanine
84. Chembl17962
85. L-histidine [usp-rs]
86. (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic Acid
87. (s)-1h-imidazole-4-alanine
88. Bdbm7953
89. Gtpl3310
90. Gtpl4670
91. L-histidine, Non-animal Source
92. Imidazole C-4(5) Deriv. 5
93. Amino-4-imidazoleproprionic Acid
94. Dtxsid9023126
95. Histidine [ep Monograph]
96. Amino-1h-imidazole-4-propanoate
97. Histidine [usp Monograph]
98. L-histidine, P.a., 98.5%
99. Bdbm181118
100. L-histidine, Cell Culture Reagent
101. 3-(1h-imidazol-4-yl)-l-alanine
102. Hy-n0832
103. Zinc6661227
104. Amino-1h-imidazole-4-propanoic Acid
105. Akos015854051
106. Akos026676613
107. Am81801
108. Ccg-204656
109. Cs-7781
110. Db00117
111. Sdccgsbi-0050549.p002
112. Serine Impurity C [ep Impurity]
113. (s)-a-amino-1h-imidazole-4-propanoate
114. Ncgc00015518-01
115. Ncgc00162189-01
116. Ncgc00162189-02
117. Ncgc00162189-05
118. Ac-35086
119. As-14171
120. (s)-alpha-amino-1h-imidazole-4-propanoate
121. (s)-alpha-amino-1h-imidazole-4-propionate
122. L-histidine, Bioultra, >=99.5% (nt)
123. H0149
124. L-histidine, Saj Special Grade, >=98.5%
125. S3989
126. C00135
127. D00032
128. D70843
129. H-2310
130. L-histidine, Reagentplus(r), >=99% (tlc)
131. M02982
132. L-histidine, Vetec(tm) Reagent Grade, >=99%
133. (s)-2-amino-3-(1h-imidazol-4-yl)propanoic Acid
134. 064h315
135. Q485277
136. B81aedb0-eaca-4296-9bab-52d60f137ffb
137. 1h-imidazole-4-propanoic Acid, .alpha.-amino-, (s)-
138. F8881-8926
139. F8889-0575
140. L-histidine, Certified Reference Material, Tracecert(r)
141. Z955123622
142. Histidine, European Pharmacopoeia (ep) Reference Standard
143. L-histidine, United States Pharmacopeia (usp) Reference Standard
144. L-histidine, Pharmaceutical Secondary Standard; Certified Reference Material
145. L-histidine, Cell Culture Tested, Meets Ep, Usp Testing Specifications, From Non-animal Source
146. L-histidine, Pharmagrade, Ajinomoto, Ep, Usp, Manufactured Under Appropriate Gmp Controls For Pharma Or Biopharmaceutical Production, Suitable For Cell Culture
| Molecular Weight | 155.15 g/mol |
|---|---|
| Molecular Formula | C6H9N3O2 |
| XLogP3 | -3.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 155.069476538 g/mol |
| Monoisotopic Mass | 155.069476538 g/mol |
| Topological Polar Surface Area | 92 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 151 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
The actions of supplemental L-histidine are entirely unclear. It may have some immunomodulatory as well as antioxidant activity. L-histidine may be indicated for use in some with rheumatoid arthritis. It is not indicated for treatment of anemia or uremia or for lowering serum cholesterol.
Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing.
Absorption
Absorbed from the small intestine via an active transport mechanism requiring the presence of sodium.
ESSENTIAL AMINO ACIDS ARE TRANSFERRED TO FETUS AGAINST A CONCN GRADIENT &, IN THE CASE OF HISTIDINE, NATURAL L-ISOMER HAS BEEN SHOWN TO CROSS SEVERAL TIMES AS FAST AS THE D-ISOMER.
LaDu, B.N., H.G. Mandel, and E.L. Way. Fundamentals of Drug Metabolism and Disposition. Baltimore: Williams and Wilkins, 1971., p. 89
PRODUCT OF OXIDATIVE DEAMINATION OR TRANSAMINATION OF L-HISTIDINE IS BETA-IMIDAZOLEPYRUVIC ACID; & PRODUCT OF DECARBOXYLATION IS HISTAMINE. HISTAMINE ENTERS OTHER PATHWAYS TO YIELD FURTHER METABOLIC PRODUCTS. /FROM TABLE/
Fenaroli's Handbook of Flavor Ingredients. Volume 2. Edited, translated, and revised by T.E. Furia and N. Bellanca. 2nd ed. Cleveland: The Chemical Rubber Co., 1975., p. 830
Since the actions of supplemental L-histidine are unclear, any postulated mechanism is entirely speculative. However, some facts are known about L-histidine and some of its metabolites, such as histamine and trans-urocanic acid, which suggest that supplemental L-histidine may one day be shown to have immunomodulatory and/or antioxidant activities. Low free histidine has been found in the serum of some rheumatoid arthritis patients. Serum concentrations of other amino acids have been found to be normal in these patients. L-histidine is an excellent chelating agent for such metals as copper, iron and zinc. Copper and iron participate in a reaction (Fenton reaction) that generates potent reactive oxygen species that could be destructive to tissues, including joints.
L-histidine is the obligate precursor of histamine, which is produced via the decarboxylation of the amino acid. In experimental animals, tissue histamine levels increase as the amount of dietary L-histidine increases. It is likely that this would be the case in humans as well. Histamine is known to possess immunomodulatory and antioxidant activity. Suppressor T cells have H2 receptors, and histamine activates them. Promotion of suppressor T cell activity could be beneficial in rheumatoid arthritis. Further, histamine has been shown to down-regulate the production of reactive oxygen species in phagocytic cells, such as monocytes, by binding to the H2 receptors on these cells. Decreased reactive oxygen species production by phagocytes could play antioxidant, anti-inflammatory and immunomodulatory roles in such diseases as rheumatoid arthritis.
This latter mechanism is the rationale for the use of histamine itself in several clinical trials studying histamine for the treatment of certain types of cancer and viral diseases. In these trials, down-regulation by histamine of reactive oxygen species formation appears to inhibit the suppression of natural killer (NK) cells and cytotoxic T lymphocytes, allowing these cells to be more effective in attacking cancer cells and virally infected cells.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Kewpie Corporation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Emulsifying Agents
Film Formers & Plasticizers
Coating Systems & Additives
Solubilizers
Topical
Controlled & Modified Release
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A L-Histidine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of L-Histidine, including repackagers and relabelers. The FDA regulates L-Histidine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. L-Histidine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of L-Histidine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A L-Histidine supplier is an individual or a company that provides L-Histidine active pharmaceutical ingredient (API) or L-Histidine finished formulations upon request. The L-Histidine suppliers may include L-Histidine API manufacturers, exporters, distributors and traders.
click here to find a list of L-Histidine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A L-Histidine DMF (Drug Master File) is a document detailing the whole manufacturing process of L-Histidine active pharmaceutical ingredient (API) in detail. Different forms of L-Histidine DMFs exist exist since differing nations have different regulations, such as L-Histidine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A L-Histidine DMF submitted to regulatory agencies in the US is known as a USDMF. L-Histidine USDMF includes data on L-Histidine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The L-Histidine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of L-Histidine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The L-Histidine Drug Master File in Japan (L-Histidine JDMF) empowers L-Histidine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the L-Histidine JDMF during the approval evaluation for pharmaceutical products. At the time of L-Histidine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of L-Histidine suppliers with JDMF on PharmaCompass.
A L-Histidine CEP of the European Pharmacopoeia monograph is often referred to as a L-Histidine Certificate of Suitability (COS). The purpose of a L-Histidine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of L-Histidine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of L-Histidine to their clients by showing that a L-Histidine CEP has been issued for it. The manufacturer submits a L-Histidine CEP (COS) as part of the market authorization procedure, and it takes on the role of a L-Histidine CEP holder for the record. Additionally, the data presented in the L-Histidine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the L-Histidine DMF.
A L-Histidine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. L-Histidine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of L-Histidine suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing L-Histidine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for L-Histidine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture L-Histidine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain L-Histidine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a L-Histidine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of L-Histidine suppliers with NDC on PharmaCompass.
L-Histidine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of L-Histidine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right L-Histidine GMP manufacturer or L-Histidine GMP API supplier for your needs.
A L-Histidine CoA (Certificate of Analysis) is a formal document that attests to L-Histidine's compliance with L-Histidine specifications and serves as a tool for batch-level quality control.
L-Histidine CoA mostly includes findings from lab analyses of a specific batch. For each L-Histidine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
L-Histidine may be tested according to a variety of international standards, such as European Pharmacopoeia (L-Histidine EP), L-Histidine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (L-Histidine USP).
LOOKING FOR A SUPPLIER?
